Country: Իռլանդիա
language: անգլերեն
source: HPRA (Health Products Regulatory Authority)
Brimonidine tartrate
Allergan Pharmaceuticals Ireland
S01EA; S01EA05
Brimonidine tartrate
0.2 percent weight/volume
Eye drops, solution
Product subject to prescription which may be renewed (B)
Sympathomimetics in glaucoma therapy1); brimonidine
Marketed
1997-11-14
Package Leaflet: Information for the user ALPHAGAN 0.2% W/V (2 MG/ML) EYE DROPS, SOLUTION brimonidine tartrate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What ALPHAGAN is and what it is used for 2. What you need to know before you use ALPHAGAN 3. How to use ALPHAGAN 4. Possible side effects 5. How to store ALPHAGAN 6. Contents of the pack and other information 1. WHAT ALPHAGAN IS AND WHAT IT IS USED FOR ALPHAGAN is used to reduce pressure within the eye. The active ingredient in ALPHAGAN is brimonidine tartrate which belongs to a group of medicines called alpha-2 adrenergic receptor agonists and works by reducing pressure within the eyeball. It can be used either alone, when beta-blocker eye drops are contraindicated, or with another eye drop, when a single medicine is not enough to lower the increased pressure in the eye, in the treatment of open angle glaucoma or ocular hypertension. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE ALPHAGAN DO NOT USE ALPHAGAN • If you are allergic (hypersensitive) to brimonidine tartrate or any of the other ingredients of this medicine (listed in section 6). • If you are taking monoamine oxidase (MAO) inhibitors or certain other antidepressants. You must inform your doctor if you are taking any antidepressant drug. • If you are breast-feeding. • In infants/babies (from birth until 2 years). WARNINGS AND PRECAUTIONS Talk to your doctor before using ALPHAGAN • If you suffer or have suffered from depression, reduced mental capacity, reduced blood supply to the read_full_document
Health Products Regulatory Authority 07 September 2020 CRN009T9G Page 1 of 8 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Alphagan 0.2% w/v (2 mg/ml) eye drops, solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml solution contains 2.0 mg brimonidine tartrate, equivalent to 1.3 mg of brimonidine. Excipient with known effect Contains benzalkonium chloride 0.05 mg/ml. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Eye drops, solution. Clear, greenish-yellow to light greenish-yellow solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension. As monotherapy in patients in whom topical beta-blocker therapy is contraindicated. As adjunctive therapy to other intraocular pressure lowering medications when the target IOP is not achieved with a single agent (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Recommended dosage in adults (including the elderly)_ The recommended dose is one drop of Alphagan in the affected eye(s) twice daily, approximately 12 hours apart. No dosage adjustment is required for the use in elderly patients. _Use in renal and hepatic impairment_ Alphagan has not been studied in patients with hepatic or renal impairment (see section 4.4). _Paediatric population_ No clinical studies have been performed in adolescents (12 to 17 years). Alphagan is not recommended for use in children below 12 years and is contraindicated in neonates and infants (less than 2 years of age) (see sections 4.3, 4.4 and 4.9). It is known that severe adverse reactions can occur in neonates. The safety and efficacy of Alphagan have not been established in children aged 2 to 12 years. Method of administration As with any eye drops, to reduce possible systemic absorption, it is recommended that the lachrymal sac be compressed at the medial canthus (punctal occlusion) for one minute. This should be performed immediately following the instil read_full_document